A D Anastasilakis
Overview
Explore the profile of A D Anastasilakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anastasilakis A, Makras P, Doulgeraki A, Polyzos S, Guarnieri V, Papapoulos S
Osteoporos Int
. 2021 May;
32(11):2377-2381.
PMID: 33987688
Primary osteoporosis is rare in children and adolescents and its optimal pharmacological management is uncertain. Bisphosphonates are commonly used while denosumab has only been administered to a few children with...
2.
Fahrleitner-Pammer A, Papaioannou N, Gielen E, Feudjo Tepie M, Toffis C, Frieling I, et al.
Arch Osteoporos
. 2017 Jun;
12(1):58.
PMID: 28643265
Purpose: Continued persistence with osteoporosis therapy is vital for fracture prevention. This non-interventional study of clinical practice evaluated medication-taking behavior of postmenopausal women receiving denosumab in Germany, Austria, Greece, and...
3.
Mpalaris V, Anagnostis P, Anastasilakis A, Goulis D, Doumas A, Iakovou I
Maturitas
. 2016 Apr;
88:32-6.
PMID: 27105694
Objective: Adipokines and ghrelin exert well-documented effects on energy expenditure and glucose metabolism. Experimental data also support a role in bone metabolism, although data from clinical studies are conflicting. The...
4.
Anastasilakis A, Makras P
Osteoporos Int
. 2015 Dec;
27(5):1929-30.
PMID: 26694593
No abstract available.
5.
Anastasilakis A, Polyzos S, Gkiomisi A, Saridakis Z, Digkas D, Bisbinas I, et al.
Osteoporos Int
. 2015 May;
26(10):2521-7.
PMID: 25990355
Unlabelled: Denosumab and zoledronic acid are potent antiresorptives. In this study in patients pre-treated with zoledronic acid, denosumab achieved similar increases with zoledronic acid in lumbar spine BMD despite the...
6.
Makras P, Athanasakis K, Boubouchairopoulou N, Rizou S, Anastasilakis A, Kyriopoulos J, et al.
Osteoporos Int
. 2015 Mar;
26(7):1949-57.
PMID: 25740208
Unlabelled: A Greek-specific cost-effectiveness analysis determined the FRAX-based intervention thresholds. Assuming a willingness to pay of 30,000 <euro>, osteoporosis treatment is cost-effective in subjects under the age of 75 with...
7.
Anastasilakis A, Polyzos S, Makras P, Gkiomisi A, Bisbinas I, Katsarou A, et al.
Osteoporos Int
. 2014 Mar;
25(5):1633-42.
PMID: 24599275
Unlabelled: In vitro data suggest that myokine irisin may affect bone metabolism by promoting osteoblast differentiation while inhibiting osteoclast differentiation. In this study, circulating irisin levels were associated with previous...
8.
Anastasilakis A, Polyzos S, Makras P, Savvides M, Sakellariou G, Gkiomisi A, et al.
Horm Metab Res
. 2013 Aug;
46(2):145-9.
PMID: 23918682
Periostin is a secreted extracellular matrix protein preferentially expressed in bone by osteocytes and periosteal osteoblasts. Reduced periostin expression may affect osteoblast differentiation and collagen type I synthesis and predispose...
9.
Polyzos S, Anastasilakis A, Terpos E
J Endocrinol Invest
. 2013 May;
36(4):280.
PMID: 23645100
No abstract available.
10.
Sakellariou G, Sayegh F, Anastasilakis A, Bisbinas I, Kapetanos G
Scand J Rheumatol
. 2013 Apr;
42(5):369-72.
PMID: 23607529
Objectives: In this study we aimed to evaluate the efficacy of disease-modifying anti-rheumatic drugs (DMARDs) for severe knee synovitis, refractory to low-dose oral corticosteroids and/or non-steroidal anti-inflammatory drugs (NSAIDs) and...